⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 6, 2024Open Access

Figure S4 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma

George A. Ward Zhiqiang Zhang Simone Jueliger Ilya S. Potapov Matthew P. Davis Adam R. Boxall Jason Taylor Harold Keer Andrea Biondo John F. Lyons Martin Sims Tomoko Smyth

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S4. Changes in DNA methylation levels after decitabine (DAC) treatment of human TCL cell lines. (Refers to Figure 2)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ward et al. (2024) studied this question.

synapsesocial.com/papers/68e65e2bb6db6435875ec86f https://doi.org/10.1158/2767-9764.25983627

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma2024
2FIGURE 4 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma2024
3FIGURE 2 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma2024
4Figure S2 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma2024
5FIGURE 3 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma2024